{"name":"Autotelicbio","slug":"autotelicbio","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":5,"colorKey":"oncology","drugs":[{"name":"ATB-101, ATB-1011, ATB-1012","genericName":"ATB-101, ATB-1011, ATB-1012","slug":"atb-101-atb-1011-atb-1012","indication":"Other","status":"phase_1"},{"name":"ATB-1011","genericName":"ATB-1011","slug":"atb-1011","indication":"Other","status":"phase_3"},{"name":"ATB-1012","genericName":"ATB-1012","slug":"atb-1012","indication":"Other","status":"phase_3"},{"name":"ATB-1013","genericName":"ATB-1013","slug":"atb-1013","indication":"Systemic sclerosis (scleroderma)","status":"phase_3"},{"name":"ATB-320","genericName":"ATB-320","slug":"atb-320","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"ATB-101, ATB-1011, ATB-1012","genericName":"ATB-101, ATB-1011, ATB-1012","slug":"atb-101-atb-1011-atb-1012","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ATB-1011","genericName":"ATB-1011","slug":"atb-1011","phase":"phase_3","mechanism":"ATB-1011 is an autotelic biologic designed to modulate immune tolerance and promote self-directed therapeutic activity.","indications":[],"catalyst":""},{"name":"ATB-1012","genericName":"ATB-1012","slug":"atb-1012","phase":"phase_3","mechanism":"ATB-1012 is an autotelic biologic designed to modulate immune tolerance and promote self-directed therapeutic activity.","indications":[],"catalyst":""},{"name":"ATB-1013","genericName":"ATB-1013","slug":"atb-1013","phase":"phase_3","mechanism":"ATB-1013 is an autotaxin inhibitor that reduces lysophosphatidic acid (LPA) production to modulate immune and fibrotic responses.","indications":["Systemic sclerosis (scleroderma)"],"catalyst":""},{"name":"ATB-320","genericName":"ATB-320","slug":"atb-320","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiV0FVX3lxTE8xeXFWMnNlS1NNb2M1b3BoYlhWUkFEM2hJR1lDRktfcC1BUWJtRy1KQ2NXd3JLN2hHVGZhOEQyaUEwWEM4VWZMTXZXY0IzQ3h1VEVaMF96NA?oc=5","date":"2020-08-12","type":"trial","source":"바이오스펙테이터","summary":"Autotelic Bio expands its management team to accelerate clinical trial for ATB-301 and ASO based platform technology development - 바이오스펙테이터","headline":"Autotelic Bio expands its management team to accelerate clinical trial for ATB-301 and ASO based platform technology dev","sentiment":"neutral"}],"patents":[],"drugCount":5,"phaseCounts":{"phase_1":2,"phase_3":3},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}